BioPorto Sells Antibody Business for $10.5M, Sharpens Focus on NGAL Biomarker
Event summary
- BioPorto divested its antibody business to Janel Life Sciences for $10.5M, with $9M paid upfront and $1.5M in potential earn-outs.
- The deal includes research-use-only antibodies, clones, inventory, and related contracts.
- BioPorto expects the divestment to extend its cash runway through H1 2028 and achieve cash flow positivity in that period.
- 2026 revenue guidance was revised downward to DKK 38-48M from DKK 48-58M, while NGAL revenue guidance remained unchanged.
- 2028 revenue aspirations were adjusted to DKK 135-185M from DKK 150-200M.
The big picture
BioPorto's divestment of its antibody business aligns with its 'Forward' strategy to concentrate on high-growth opportunities, particularly its NGAL biomarker for acute kidney injury. The $10.5M transaction enhances financial flexibility and extends the company's cash runway, though it comes at the cost of reduced near-term revenue. The move reflects a broader trend in biotech of streamlining portfolios to focus on core assets with the highest long-term potential.
What we're watching
- Execution Risk
- Whether BioPorto can meet the commercial milestones required to earn the $1.5M earn-out.
- Market Adoption
- The pace at which BioPorto can drive adoption of its NGAL biomarker following the divestment.
- Financial Flexibility
- How the $10.5M proceeds will be deployed to support BioPorto's path to cash flow positivity.
Related topics